US FDA News 3/3

top of page

FDA Approved diabetic treatments | 2023 |

FDA Approved diabetic treatments | 2023 |

FDA Approved diabetic treatments | 2023 |

ipharmaservices

Jun 28, 2023

FDA Approved Myasthenia gravis treatments | News | Updates | iPharmaCenter

ipharmaservices

Jun 27, 2023

US FDA approved drugs for Duchenne Muscular Dystrophy | Elevidys | Viltepso | iPharmaCenter

ipharmaservices

Jun 23, 2023

FDA News and Updates | US Pharma News | iPharmaCenter

FDA News and Updates | US Pharma News | iPharmaCenter

FDA News and Updates | US Pharma News | iPharmaCenter

ipharmaservices

Jun 21, 2023

2022 FDA Drug Approvals | US Pharma News | iPharmaCenter

2022 FDA Drug Approvals | US Pharma News | iPharmaCenter

2022 FDA Drug Approvals | US Pharma News | iPharmaCenter

ipharmaservices

Feb 7, 2023

US FDA Withdrawals | News | Blenrep was withdrawn from the US market | iPharmaCenter

US FDA Withdrawals | News | Blenrep was withdrawn from the US market | iPharmaCenter

US FDA Withdrawals | News | Blenrep was withdrawn from the US market | iPharmaCenter

ipharmaservices

Nov 23, 2022

US FDA approved BMS Sotyktu (deucravacitinib) for moderate to severe plaque psoriasis |iPharmaCenter

US FDA approved BMS Sotyktu (deucravacitinib) for moderate to severe plaque psoriasis |iPharmaCenter

US FDA approved BMS Sotyktu (deucravacitinib) for moderate to severe plaque psoriasis |iPharmaCenter

ipharmaservices

Sep 11, 2022

bluebird bio's $2.8 million gene therapy Zynteglo received FDA nod for beta-thalassemia

bluebird bio's $2.8 million gene therapy Zynteglo received FDA nod for beta-thalassemia

bluebird bio's $2.8 million gene therapy Zynteglo received FDA nod for beta-thalassemia

ipharmaservices

Aug 19, 2022

BMS' Breyanzi was approved for relapsed or refractory LBCL | News | FDA | iPharmacenter

BMS' Breyanzi was approved for relapsed or refractory LBCL | News | FDA | iPharmacenter

BMS' Breyanzi was approved for relapsed or refractory LBCL | News | FDA | iPharmacenter

ipharmaservices

Jun 25, 2022

FDA approved two Opdivo based regimens as a 1L treatment for ESCC | FDA News | iPharmaCenter

FDA approved two Opdivo based regimens as a 1L treatment for ESCC | FDA News | iPharmaCenter

FDA approved two Opdivo based regimens as a 1L treatment for ESCC | FDA News | iPharmaCenter

ipharmaservices

May 30, 2022

FDA approved Kymriah for follicular lymphoma | Novartis | News | Cancer | | Updates | iPharmaCenter

FDA approved Kymriah for follicular lymphoma | Novartis | News | Cancer | | Updates | iPharmaCenter

FDA approved Kymriah for follicular lymphoma | Novartis | News | Cancer | | Updates | iPharmaCenter

ipharmaservices

May 29, 2022

FDA gave the nod to Pfizer's Paxlovid | Pfizer to supply 2.5 million doses of Paxlovid to the UK

FDA gave the nod to Pfizer's Paxlovid | Pfizer to supply 2.5 million doses of Paxlovid to the UK

FDA gave the nod to Pfizer's Paxlovid | Pfizer to supply 2.5 million doses of Paxlovid to the UK

ipharmaservices

Dec 23, 2021

~$10 bn acquisition paying off for Novartis as FDA approved Novartis' Leqvio

~$10 bn acquisition paying off for Novartis as FDA approved Novartis' Leqvio

~$10 bn acquisition paying off for Novartis as FDA approved Novartis' Leqvio

ipharmaservices

Dec 23, 2021

Gilead’s Trodelvy approved for triple-negative breast cancer in US

Gilead’s Trodelvy approved for triple-negative breast cancer in US

Gilead’s Trodelvy approved for triple-negative breast cancer in US

ipharmaservices

Apr 9, 2021

FDA to review the accelerated approvals of Keytruda, Opdivo, and Tecentriq

FDA to review the accelerated approvals of Keytruda, Opdivo, and Tecentriq

FDA to review the accelerated approvals of Keytruda, Opdivo, and Tecentriq

ipharmaservices

Mar 13, 2021

FDA approved Roche’s Gavreto for RET fusion-positive NSCLC

FDA approved Roche’s Gavreto for RET fusion-positive NSCLC

FDA approved Roche’s Gavreto for RET fusion-positive NSCLC

ipharmaservices

Sep 7, 2020

bottom of page